InsiderSignal.AI

InsiderSignal.ai

VTRS - Viatris Inc

Insider Purchase by Smith Scott Andrew (CEO)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Smith Scott Andrew, serving as CEO at Viatris Inc (VTRS), purchased 22,000 shares at $9.99 per share, for a total transaction value of $219,740.00. Following this transaction, Smith Scott Andrew now holds 314,807 shares of VTRS.

This purchase represents a 8.00% increase in Smith Scott Andrew's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, August 12, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, August 13, 2025, 1 day after the trade was made.

Viatris Inc operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Smith Scott Andrew

CEO

Scott A. Smith is a seasoned healthcare executive with over 35 years of experience in the biotechnology and pharmaceutical industries. Born in 1961, he joined the Viatris Inc. (NASDAQ: VTRS) Board of Directors in December 2022 and was appointed Chief Executive Officer effective April 1, 2023, to lead the execution of the company's Phase 2 strategic plan for renewed growth.[[1]](https://www.prnewswire.com/news-releases/viatris-announces-appointment-of-scott-a-smith-as-ceo-effective-april-1-2023-301756490.html)[[2]](https://www.viatris.com/en/about-us/board-of-directors/scott-a-smith)[[3]](https://fintool.com/app/research/companies/VTRS/people/scott-a-smith)[[5]](https://www.viatris.com/en/about-us/executive-leadership-team/scott-smith) Smith's career highlights include serving as President of BioAtla, Inc. (2018-2023), where he built clinical development structures advancing multiple assets into late-stage trials, drove strategic operations, and led business development.[[2]](https://www.viatris.com/en/about-us/board-of-directors/scott-a-smith)[[3]](https://fintool.com/app/research/companies/VTRS/people/scott-a-smith)[[5]](https://www.viatris.com/en/about-us/executive-leadership-team/scott-smith) Previously, at Celgene Corporation (2008-2018), he rose from Senior Vice President and Global Head of Immunology to President of Inflammation and Immunology, and ultimately President and Chief Operating Officer, overseeing the clinical development, launch, and global commercial success of the blockbuster drug Otezla.[[1]](https://www.prnewswire.com/news-releases/viatris-announces-appointment-of-scott-a-smith-as-ceo-effective-april-1-2023-301756490.html)[[2]](https://www.viatris.com/en/about-us/board-of-directors/scott-a-smith)[[3]](https://fintool.com/app/research/companies/VTRS/people/scott-a-smith) As Viatris CEO, he leverages his expertise in managing complex organizations, regulatory strategies, and business development.[[1]](https://www.prnewswire.com/news-releases/viatris-announces-appointment-of-scott-a-smith-as-ceo-effective-april-1-2023-301756490.html)[[4]](https://www.viatris.nl/en-nl/over-viatris/ons-management/scott-smith)

View full insider profile →

Trade Price

$9.99

Quantity

22,000

Total Value

$219,740.00

Shares Owned

314,807

Trade Date

Tuesday, August 12, 2025

194 days ago

SEC Filing Date

Wednesday, August 13, 2025

Filed 1 day after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Viatris Inc

Company Overview

No company information available
View news mentioning VTRS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/125823

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime